Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy, Safety, and Pharmacokinetics of Shu Yang IVIG in Patients With Primary Immunodeficiency

NCT06089122 is registered in ClinicalTrials.gov with Azidus Brasil as lead sponsor.

NCT NCT06089122
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06089122 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy, Safety, and Pharmacokinetics of Shu Yang IVIG in Patients With Primary Immunodeficiency
Lead sponsor
Azidus Brasil
Phase
Phase 3
Overall status
Unknown status
Start date
April 30, 2024
Completion date
June 8, 2025
Enrollment
50 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

primary immunodeficiency disease